Emerging evidence reveals a clinically significant rebound effect following the discontinuation of glucagon-like peptide-1 ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) ...

The National Institute for Health and Care Excellence (NICE) has published updated guidance recommending Forxiga ...

What else is there to share? As it happens, quite a lot. Last time I spoke about the diagnosis of Young Onset Parkinson’s disease (YOPD), how this presented several day-to-day challenges from securing ...